ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Shares Purchased by Quest Partners LLC

Quest Partners LLC boosted its stake in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) by 253.2% during the second quarter, Holdings Channel.com reports. The institutional investor owned 10,378 shares of the company’s stock after acquiring an additional 7,440 shares during the period. Quest Partners LLC’s holdings in ORIC Pharmaceuticals were worth $73,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the stock. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of ORIC Pharmaceuticals by 162.3% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,152 shares of the company’s stock valued at $36,000 after acquiring an additional 3,188 shares during the last quarter. ProShare Advisors LLC purchased a new position in ORIC Pharmaceuticals in the 1st quarter valued at about $161,000. China Universal Asset Management Co. Ltd. boosted its stake in shares of ORIC Pharmaceuticals by 104.9% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 12,922 shares of the company’s stock worth $178,000 after purchasing an additional 6,617 shares during the last quarter. Virtu Financial LLC purchased a new stake in shares of ORIC Pharmaceuticals during the first quarter worth about $225,000. Finally, Rhumbline Advisers raised its position in shares of ORIC Pharmaceuticals by 53.7% in the second quarter. Rhumbline Advisers now owns 92,702 shares of the company’s stock valued at $655,000 after buying an additional 32,402 shares during the last quarter. Institutional investors and hedge funds own 95.05% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on ORIC shares. Oppenheimer lowered their price objective on ORIC Pharmaceuticals from $17.00 to $15.00 and set an “outperform” rating for the company in a research report on Tuesday, August 13th. Wedbush reaffirmed an “outperform” rating and issued a $20.00 target price on shares of ORIC Pharmaceuticals in a research report on Tuesday, September 10th. Cantor Fitzgerald reissued an “overweight” rating on shares of ORIC Pharmaceuticals in a research report on Monday, September 9th. Stifel Nicolaus began coverage on shares of ORIC Pharmaceuticals in a research report on Friday, September 6th. They set a “buy” rating and a $20.00 price target on the stock. Finally, HC Wainwright reissued a “buy” rating and issued a $21.00 price objective on shares of ORIC Pharmaceuticals in a research report on Wednesday, August 14th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $18.00.

ORIC Pharmaceuticals Stock Up 1.1 %

NASDAQ ORIC opened at $10.10 on Wednesday. ORIC Pharmaceuticals, Inc. has a fifty-two week low of $5.27 and a fifty-two week high of $16.65. The business has a 50 day moving average price of $9.98 and a two-hundred day moving average price of $10.04. The stock has a market cap of $712.45 million, a PE ratio of -5.61 and a beta of 1.12.

ORIC Pharmaceuticals (NASDAQ:ORIC) last announced its earnings results on Monday, August 12th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.03). Sell-side analysts anticipate that ORIC Pharmaceuticals, Inc. will post -1.78 EPS for the current fiscal year.

ORIC Pharmaceuticals Company Profile

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.